Biogen and Denali report Phase IIb LUMA trial data for Parkinson’s

The trial included 648 patients aged 30 to 80 years with early-stage Parkinson’s disease. Credit: R Photography Background / ...

Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback

Shares of Biogen (BIIB) and Denali Therapeutics (DNLI) fell in the premarket on Friday after the companies announced a decision to discontinue the development of BIIB122, an experimental therapy for ...
Science News

New tools may help diagnose Parkinson’s earlier than ever

From special pens to earwax evaluations, a plethora of emerging diagnostics could one day be a major boon for people with the ...